Biography
Maureen Rutten-van Mölken is Professor of Economic Evaluation of Innovations for Health at the Erasmus School of Health Policy & Management, Erasmus University Rotterdam. She is also the Scientific Director of the Institute for Medical Technology Assessment (IMTA).
She teaches “Health Technology Assessment” and “Pharmaceutical Pricing and Market Access” in the Master-program Health Economics Policy and Law at Erasmus University Rotterdam.
Her expertise includes economic evaluation studies, either alongside clinical trials or using probabilistic decision-analytic modeling, and outcomes research. She worked in many disease areas, including respiratory diseases (COPD, asthma), rheumatology, diabetes, cardiovascular disease, and Pompe disease. She has a special interest in the cost-effectiveness and the financing and payment of complex multi-faceted interventions that involve system-level changes like integrated care programs, disease management programs, hospital at home programs, outpatient rehabilitation programs, etc. She also has an interest in the health economics of personalized medicine.
She has almost 30 years of experience and has been leading many applied economic evaluations and HTA methods-studies leading to high-level publications. She is the coordinator of SELFIE, a Horizon2020 project on integrated care in multi-morbidity, and contributes to Horizon2020 project HEcoPerMed that develops guidance on health economic modeling, and financing and payment strategies for personalized medicine.
She was trained as a health scientist and had additional training in health economics and epidemiology. She obtained an MSc in Health Care Policy and Management at Maastricht University (1988), and a PhD in Health Economics, also at Maastricht University (1994). She joined iMTA as a Senior Researcher in 1996. Previously, she was an Assistant Professor in Health Economics and Medical Technology Assessment at the Department of Health Economics of the University of Maastricht.
Erasmus School of Health Policy & Management
- m.rutten@eshpm.eur.nl
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- Jan A. Witte, Erwin Birnie, Gert-Jan Braunstahl, Edmée van den Akker, Walter J.M. van Litsenburg, Niels H. Chavannes, Maureen van Molken & Johannes C.C.M. in ’t Veen (2023) - Implementing integrated care guidelines in asthma and COPD: It ain’t easy! - Heliyon, 9 (11) - doi: 10.1016/j.heliyon.2023.e21540 - [link]
- Maureen van Molken, Matthijs Versteegh, Balázs Nagy & Sarah Wordsworth (2023) - HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead - Personalized Medicine, 20 (4), 299-303 - doi: 10.2217/pme-2022-0074
- Gábor Kovács, Dávid Nagy, László Szilberhorn, Tamás Zelei, Zsolt Gaál, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth & Balázs Nagy (2023) - Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young - Personalized Medicine, 20 (4), 375-385 - doi: 10.2217/pme-2023-0023 - [link]
- Balázs Nagy, Tamás Zelei, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth & László Szilberhorn (2023) - Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies - Personalized Medicine, 20 (4), 401-411 - doi: 10.2217/pme-2023-0040
- László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth & Balázs Nagy (2023) - Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries - Personalized Medicine, 20 (4), 387-399 - doi: 10.2217/pme-2023-0017
- Rositsa Koleva-Kolarova, Heleen Vellekoop, Matthijs Versteegh, Maureen van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth & Apostolos Tsiachristas (2023) - Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems - Personalized Medicine, 20 (4), 357-374 - doi: 10.2217/pme-2022-0133
- Chiara Whichello, Ian Smith, Jorien Veldwijk, G. Ardine de Wit, Maureen P.M.H. Rutten- van Molken & Esther W. de Bekker-Grob (2023) - Discrete choice experiment versus swing-weighting: A head-to-head comparison of diabetic patient preferences for glucose-monitoring devices - PLoS ONE, 18 (7 JULY) - doi: 10.1371/journal.pone.0283926 - [link]
- Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken & (2023) - Cost-effectiveness of alternative <i>NTRK </i>testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries - Personalized Medicine, 20 (4), 321-338 - doi: 10.2217/pme-2022-0070 - [link]
- Rositsa Koleva-Kolarova, László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Balázs Nagy, Simone Huygens, Matthijs Versteegh, Maureen Rutten van Mölken, Sarah Wordsworth & Apostolos Tsiachristas (2023) - Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation - Personalized Medicine, 20 (4), 305-319 - doi: 10.2217/pme-2022-0145 - [link]
- Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth & Apostolos Tsiachristas (2023) - Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK - Personalized Medicine, 20 (4), 339-355 - doi: 10.2217/pme-2022-0099
Master Thesis HE
- Year Level
- master, master
- Year
- 2023
- Course Code
- GW4592M
Health Technology Assessment
- Year Level
- master, master, master
- Year
- 2023
- Course Code
- GW4546M
Pharmaceutical Pricing and Market Access
- Year Level
- master, master, master, master
- Year
- 2023
- Course Code
- GW4575M
Health Technology Assessment (Eu-HEM)
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4585M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4555M
Master HEPL-HE 2023-2024
- Year
- 2023
- Course Code
- GWMTTHEPL
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4560M